Scientific Program 

Wednesday, September 11, 2024

 18:00-19:00 Satellite Symposium
Hot topics in breast cancer
Supported by Baylor St. Luke’s Medical Center
Hall A
Chairpersons Shaheenah Dawood, Dubai, UAE
Stephen Grobmyer, Abu Dhabi, UAE
18:00-18:20 How to sequence the new strategies in metastatic TNBC
Javier Cortes, Barcelona, Spain 
18:20-19:00
18:20
18:35
18:50
Debate: That TAD is appropriate for those with cN2 disease at presentation
Yes: Bruce Mann, Melbourne, Australia
No: Alastair Thompson, Houston, TX, USA
Discussion

Friday, September 8, 2023

09:00-09:15 Congress Opening Hall A
Chairpersons Shaheenah Dawood, Dubai, UAE
Bruce Mann, Melbourne, Australia
Welcome from Congress chairpersons

 

09:15-10:20 Session 1: Neoadjuvant therapy Hall A
Chairpersons Shaheenah Dawood, Dubai, UAE
Bruce Mann, Melbourne, Australia
09:15-09:45
09:15
09:25
09:35
Debate: That T1C HER2 positive breast cancer should have neoadjuvant therapy
Yes: Kefah Mokbel, London, UK
No: Meteb Al-Foheidi, Jeddah, Saudi Arabia
Discussion
09:50-10:05 Management of the initially positive axilla
Stephen Grobmyer, Abu Dhabi, UAE
10:05-10:20 Which patients with luminal cancer should be considered for neoadjuvant endocrine therapy?
Fathi Azribi, Dubai, UAE

 

10:20-10:55 Coffee break, poster viewing and exhibition visit  

 

10:55-12:00 Session 2: HR+ breast cancer Hall A
Chairpersons Hassan Shahryar, Abu Dhabi, UAE
Sonia Otsmane, Abu Dhabi, UAE
10:55-11:10 ER testing in breast cancer
Asif Quadri, Abu Dhabi, UAE
11:10-11:20 Which patients with HR positive/HER2 negative should be offered CDKi’s?
Nouri Bennini, Abu Dhabi, UAE
11:20-11:50 Update on CDK4/6 inhibitors in metastatic breast cancer
Javier Cortes, Barcelona, Spain
11:50-12:00 What is the best option when a patient progresses on a CDK4/6 inhibitor?
Dalia Elshorbagy, Dubai, UAE

 

12:00-13:00     Lunch break, poster viewing and exhibition visit

 

13:00-14:15 Session 3: Therapy – management of low risk invasive breast cancer Hall A
Chairpersons Rana Irfan Mahmood, Dubai, UAE
Stephen Grobmyer, Abu Dhabi, UAE
13:00-13:15 Use of assays
Alastair Thompson, Houston, TX, USA
13:15-13:30 Small trial
Stuart MacIntosh, Belfast, UK
13:30-13:45 PROSPECT
Bruce Mann, Melbourne, Australia
13:45-14:15 Discussion
Moderator: Stephen Grobmyer, Abu Dhabi, UAE
Panelists: Alastair Thompson, Houston, TX, USA;  Stuart MacIntosh, Belfast, UK;  Bruce Mann, Melbourne, Australia;
Fady Geara, Abu Dhabi, UAE

 

14:15-15:30 Session 4: Advanced triple negative disease  Hall A
Chairpersons Bassim Al Bahrani, Oman
Dalia Elshorbaby, Dubai, UAE
14:15-14:30 Novel emerging therapeutic modalities for advanced triple negative breast cancer
Shaheenah Dawood, Dubai, UAE
14:30-15:00
14:30
14:40
14:50
Debate: Post immunotherapy: Is ENHERTU® the treatment of choice?
Yes: Hassan Shahryar, Abu Dhabi, UAE
No: Fathi Azribi, Dubai, UAE
Discussion
15:00-15:10 Free Paper:
The value of early increases in cardiac troponin and natriuretic peptides for asymptomatic chemotherapy-linked cardiotoxicity detection in breast cancer patients
Saule Balmagambetova,
Aktobe, Kazakhstan

 

 15:10-15:30 Tumour Board
Hall A
Moderator Javier Cortes, Barcelona, Spain
Panelists Rana Irfan Mahmood, Dubai, UAE;  Sonia Otsmane, Abu Dhabi, UAE;  Bassim Al Bahrani, Oman

 

15:30-15:45 Coffee break, poster viewing and exhibition visit  

 

 15:45-17:15 Session 5: Imaging Hall A
Chairpersons Aly Abdel Razek, Abu Dhabi, UAE
Khalid Saeed Balaraj, Abu Dhabi, UAE
15:45-16:15 The role of MRI in breast cancer
Karla Sepulveda, Houston, TX, USA
16:15-16:25 Free Paper:
Cancer diagnosis by clinical breast exam in BRCA carrier vs. intermediate to average risk women
Tehillah Menes, Ramat Gan, Israel
16:25-16:35 Free Paper:
Shearwave elastography of the breast to characterise breast lesions
Natalie Clements, Bunbury, Australia
16:35-17:05
16:35
16:45
16:55
Debate: That all patients with early breast cancer should have preoperative contrast based imaging
Yes: Bruce Mann, Melbourne, Australia
No: Stuart McIntosh, Belfast, UK
Discussion

 

Saturday, September 9, 2023

09:00-10:00 Session 6: HER2 low breast cancer Hall A
Chairpersons Abdul Rahman El Kinge, Dubai, UAE
Nouri Bennini,
Abu Dhabi, UAE
09:00-09:15 Antibody-drug conjugates (ADCs)
Javier Cortes, Barcelona, Spain
09:15-09:30 Challenges in reporting HER2-low breast cancer: A pathologist’s prospective
Basel Atrabulsi, Abu Dhabi, UAE
09:30-10:00
09:30
09:40
09:50
Debate: In HER2 low, hormone negative metastatic breast cancer, TDXd should be preferred over sacituzumab govitecan
Yes: Mohsen Mokhtar, Cairo, Egypt
No: Abdul Rahman El Kinge, Dubai, UAE
Discussion

 

 10:00-10:20 Tumour Board Hall A
Moderator Hassan Shahryar, Abu Dhabi, UAE
Panelists Dalia Elshorbagy, Dubai, UAE;  Kaltar Das, Dubai, UAE;  Annett Hamadi, Dubai, UAE; Aladdin Marraoui, Abu Dhabi, UAE

 

10:20-11:35 Session 7: Breast reconstruction Hall A
Chairpersons Archana Shetty, Dubai, UAE
Raffi Gurunian, Abu Dhabi, UAE
10:20-10:45 Breast surgical reconstruction
Sebastian Winocour, Houston, TX, USA
10:45-11:00 Free Paper:
Long-term patient-reported outcomes in women undergoing mastectomy with and without delayed breast reconstruction in a population-based cohort
Shelley Potter, Bristol, UK
11:00-11:10
Free Paper:
Clinical and patient-reported outcomes following delayed-immediate autologous breast reconstruction after post-mastectomy radiotherapy: Are sacrificial implants good practice?
Saud Hamza, Perth, Australia
11:10-11:35
Case discussion:
Approaches to breast reconstruction in a patient who requires PMRT
Moderator: Archana Shetty, Dubai, UAE
Panelists: Raffi Gurunian, Abu Dhabi, UAE;  Fady Geara, Abu Dhabi, UAE;  Shelly Potter, Bristol, UK;  Saud Hamza, Perth, Australia

 

11:35-11:50 Coffee break, poster viewing and exhibition visit  

 

 11:50-12:50 Satellite Symposium:
Disruptive innovation: Harness the power of RADAR
Supported by Merit Medical
Hall A
Chairperson Kefah Mokbel, London, UK
11:50-12:20 Shining light on precision: Navigating non-palpable breast lesions with SCOUT® Radar Localization
Kefah Mokbel, London, UK
12:20-12:50 Advanced applications with SCOUT® Radar Localization
Kayla Griffith, Denver, CO, USA
12:50-13:00 Free Paper:
Indocyanine green as a practical and viable alternative to blue dye or lymphoscintigraphy in sentinel node mapping
Michael Law,
Melbourne, Australia
13:00-13:10 Free Paper:
Diagnostic accuracy of sentinel lymph node biopsy using indocyanine green compared to technetium-99 radioisotope with methylene blue dye in N0 early breast cancer: A systematic review
Naresh Kumar,
Mangalagiri, India

 

13:10-13:40 Lunch break, poster viewing and exhibition visit  
Chairpersons    

 

13:40-14:20 Session 8: When is less better? Hall A
Chairpersons Abdul Rahman El Kinge, Dubai, UAE
Aladdin Marraoui,
Abu Dhabi, UAE
13:40-13:50  Optimising function outcomes
Alastair Thompson, Houston, TX, USA
13:50-14:00  Optimising radiation therapy following breast conserving therapy
Fady Geara, Abu Dhabi, UAE
14:00-14:10  De-escalation of oncoplastic surgery
Tibor Kovac, Abu Dhabi, UAE
14:10-14:20 Molecular test to reduce chemotherapy
Fathi Azribi, Dubai, UAE

 

 14:20-14:35 Congress closing and Award presentation Hall A
Chairpersons Shaheenah Dawood, Dubai, UAE
Bruce Mann, Melbourne, Australia

 

Skip to content